Comparison of Food and Drug Administration expedited approvals and guideline updates: A case study of immune checkpoint inhibitors in colon cancer care.
- DOI
- 10.1016/j.canlet.2025.217979
- Published
- 2025-08-12
- Container
- Cancer Lett
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.canlet.2025.217979,
title = {Comparison of Food and Drug Administration expedited approvals and guideline updates: A case study of immune checkpoint inhibitors in colon cancer care.},
author = {Horn DM and Phillips KA and Schulman KA.},
year = {2025},
journal = {Cancer Lett},
doi = {10.1016/j.canlet.2025.217979},
url = {https://doi.org/10.1016/j.canlet.2025.217979}
}RIS
TY - JOUR TI - Comparison of Food and Drug Administration expedited approvals and guideline updates: A case study of immune checkpoint inhibitors in colon cancer care. AU - Horn DM AU - Phillips KA AU - Schulman KA. PY - 2025 JO - Cancer Lett DO - 10.1016/j.canlet.2025.217979 UR - https://doi.org/10.1016/j.canlet.2025.217979 ER -
APA
DM, H., KA, P., & KA., S. (2025). Comparison of Food and Drug Administration expedited approvals and guideline updates: A case study of immune checkpoint inhibitors in colon cancer care.. Cancer Lett. https://doi.org/10.1016/j.canlet.2025.217979
Source records
- europe-pmc · retrieved 2026-09-25T21:38:48.161Z